NASDAQ:MESO
Mesoblast Ltd Stock News
$7.35
+0.330 (+4.70%)
At Close: May 17, 2024
Appendix 4C Quarterly Activity Report
08:06pm, Thursday, 29'th Jul 2021
Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2021
Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
06:45am, Monday, 19'th Jul 2021
Mesoblast Limited (NASDAQ: MESO) has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respira
NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
08:15pm, Thursday, 15'th Jul 2021
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from t
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
07:46pm, Wednesday, 30'th Jun 2021
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy
Operational Highlights and Financial Results for the Period Ended March 31, 2021
08:01pm, Wednesday, 02'nd Jun 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights an
Mesoblast Corporate Update and Financial Results Webcast
06:01pm, Wednesday, 02'nd Jun 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss ope
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?
11:16am, Monday, 03'rd May 2021
Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Why Mesoblast Limited Stock Is Jumping Today
04:06pm, Friday, 30'th Apr 2021
The company announced positive results from a clinical trial.
MESO Stock: From $7.22 To $8.99 Explanation
12:09pm, Friday, 30'th Apr 2021
The stock price of Mesoblast Limited (Nasdaq: MESO) increased from $7.22 to a day high of $8.99 during intraday trading this morning. This is why it happened.
Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress
09:21am, Friday, 30'th Apr 2021
Mesoblast Limited (NASDAQ: MESO) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (A
Appendix 4C Quarterly Activity Report
08:47pm, Thursday, 29'th Apr 2021
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021
Mesoblast Corporate Update
07:08pm, Thursday, 29'th Apr 2021
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a
Mesoblast Operational Highlights and Upcoming Milestones
07:54pm, Tuesday, 30'th Mar 2021
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Compa
BioCardia Is Super Cheap With Multiple Shots On Goal
01:57pm, Thursday, 25'th Mar 2021
BioCardia Is Super Cheap With Multiple Shots On Goal
